Recent Updates
Recently added Catalysts
SRPT Positive Sentiment

Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Key Takeaway: Sarepta Therapeutics will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. The presentation will showcase the company's advancements in precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy and limb-girdle muscular dystrophies. A Q&A session will follow the presentation, which will also be available via live webcast.
Price reaction · baseline $129.58 (2022-12-30 close) · hit pre-market · clean, no other SRPT news in the window
day 0 close · peak
-3.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sarepta Therapeutics is a leader in precision genetic medicine.
  • The company has a vast pipeline with over 40 programs in development.
  • The presentation at a prestigious conference highlights their ongoing efforts.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
16.8%
average across 4 past catalysts
Lead asset
Eteplirsen
Phase 3 · Muscular Dystrophy, Duchenne

Full Press Release Details

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023 at 1:30 p.m. E.T. / 10:30 a.m. P.T. Following the presentation there will be a Q&A session starting at 1:50 p.m. E.T. / 10:50 a.m. P.T.
The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta’s website athttps://investorrelations.sarepta.com/events-presentationsand will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta TherapeuticsSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visitwww.sarepta.comor follow us onTwitter,LinkedIn,InstagramandFacebook.
Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.

Investor Contact:Ian Estepan, 617-274-4052iestepan@sarepta.com

Media Contact:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com

Frequently Asked Questions

When will Sarepta present at the J.P. Morgan Conference?

Sarepta will present on January 9, 2023, at 1:30 p.m. E.T.

Where can I watch Sarepta's presentation?

The presentation will be webcast live on Sarepta's investor relations website.

What topics will Sarepta cover in their presentation?

Sarepta will discuss advancements in precision genetic medicine for rare diseases.

How long will the presentation be available online?

The webcast will be archived for 90 days after the presentation.

Last updated: Jan 3, 2023